XML 63 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1

Consolidated Entities and Acquisitions (Tables)

12 Months Ended

Dec. 31, 2024

Consolidated Entities and Acquisitions [Line Items]

Pro Forma Information

The following table presents certain unaudited pro-forma financial information for the year ended December 31, 2022 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis’ common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.

		Year Ended December 31,
(In thousands)		2022
Revenue		$	357,880
Net income		$	204,987
Net income attributable to Innoviva stockholders		$	214,390

Entasis Therapeutics Holdings Inc

Consolidated Entities and Acquisitions [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:

(In thousands)		February 17, 2022
Cash and cash equivalents		$	23,070
Prepaid expenses			5,554
Other current assets			1,959
Property and equipment, net			185
Right-of-use assets			959
Goodwill			11,493
Intangible assets			106,700
Other assets			302
Total assets acquired		$	150,222
Accounts payable		$	1,583
Accrued personnel-related expenses			1,058
Other accrued liabilities			5,096
Deferred tax liabilities			7,769
Total liabilities assumed		$	15,506
Total assets acquired, net		$	134,716

La Jolla Pharmaceutical Company

Consolidated Entities and Acquisitions [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:

(In thousands)		August 22, 2022
Cash and cash equivalents		$	47,415
Short-term marketable securities			471
Accounts receivable			5,876
Inventory			66,200
Prepaid expenses			1,261
Other current assets			907
Property and equipment, net			13
Right-of-use assets			226
Goodwill			6,411
Intangible assets			151,000
Deferred tax assets			7,461
Other assets			710
Total assets acquired		$	287,951
Accounts payable		$	1,237
Deferred revenue			2,849
Other accrued liabilities			11,362
Other long-term liabilities			65,944
Total liabilities assumed		$	81,392
Total assets acquired, net		$	206,559

Theravance Respiratory Company, LLC

Consolidated Entities and Acquisitions [Line Items]

Summary of Financial Information of TRC

(In thousands)
Royalty revenue		$	72,029
Operating expenses			(332	)
Income from operations			71,697
Other income, net			10
Realized loss			(39,386	)
Income tax expense, net			1
Changes in fair values of equity and    long-term investments, net			(8,884	)
Net income		$	23,438

ISP Fund LP

Consolidated Entities and Acquisitions [Line Items]

Summary of Individual Investments Held by ISP Fund

The following is a summary of individual investments held by ISP Fund at each balance sheet date:

		December 31,
In thousands		2024				2023
Common stock - Publicly traded healthcare companies
United States		$	84,039			$	184,926
United Kingdom			1,989				2,942
Total common stock			86,028				187,868
Preferred stock - Privately held healthcare companies
United States			53,591				52,530
Warrants - Privately held healthcare companies			8,507				8,075
Money market fund and cash			107,532				63,339
Total investments held by ISP Fund LP		$	255,658			$	311,812

X

- Definition

Consolidated entities and acquisitions.

+ References

No definition available.

+ Details

Name:	inva_ConsolidatedEntitiesAndAcquisitionsLineItems
Namespace Prefix:	inva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of financial Information on consolidated entity.

+ References

No definition available.

+ Details

Name:	inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock
Namespace Prefix:	inva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-SubTopic 10
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-SubTopic 10
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

Name:	us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investment.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/320/tableOfContent

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Topic 321
-Publisher FASB
-URI https://asc.fasb.org/321/tableOfContent

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Topic 325
-Publisher FASB
-URI https://asc.fasb.org/325/tableOfContent

+ Details

Name:	us-gaap_InvestmentTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Paragraph 1
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

+ Details

Name:	us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: